Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon
Uncommon EGFR mutations in NSCLC
Date
14 Sep 2020Session
Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizonPresenters
Zofia PiotrowskaAuthors
M. Krebs1, Z. Piotrowska2Author affiliations
- 1 Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
- 2 Hematology/oncology, Massachusetts General Hospital, 02114 - Boston/US
Resources
Resources from the same session
Looking to the future: How can emerging therapeutic options influence the management landscape?
Presenter: Benjamin Besse
Session: Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon
Resources:
Webcast
Live Q&A - 18 September 2020 - 15:30-16:00
Presenter: Pilar Garrido
Session: Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon
Resources:
Webcast
An overview of NSCLC
Presenter: Marina Garassino
Session: Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon
Resources:
Webcast